Navigation Links
Biodel Reports Research Progress in Poster Session on Short-Acting Insulins at 46th EASD Annual Meeting
Date:9/23/2010

ce or achievements to differ materially from those described or implied in the forward-looking statements, including, but not limited to, our ability to secure FDA approval for Linjeta(TM) and our other product candidates under Section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act; our ability to market, commercialize and achieve market acceptance for product candidates developed using our VIAdel(TM) technology, particularly Linjeta(TM) the progress or success of our research, development and clinical programs and the initiation and completion of our clinical trials; the FDA's findings regarding data anomalies observed in India in our Phase 3 clinical trial of Linjeta(TM) for patients with Type 1 diabetes; the possibility that patients taking Linjeta(TM) may experience more injection site discomfort than they experience with competing products; our ability to protect our intellectual property and operate our business without infringing upon the intellectual property rights of others; our estimates of future performance; our ability to enter into collaboration arrangements for the commercialization of our product candidates and the success or failure of those collaborations after consummation, if consummated; the rate and degree of market acceptance and clinical utility of our products; our commercialization, marketing and manufacturing capabilities and strategy; our estimates regarding anticipated operating losses, future revenues, capital requirements and our needs for additional financing; and other factors identified in our most recent quarterly report on Form 10-Q for the quarter ended June 30, 2010. The company disclaims any obligation to update any forward-looking statements as a result of events occurring after the date of this press release.

BIOD-G

CONTACT:  Seth Lewis, +1-646-378-2952


'/>"/>
SOURCE Biodel Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Biodel Appoints Arthur Urciuoli to its Board of Directors
2. Biodel to Raise $9.4 Million Through Registered Direct Offering
3. Biodel Announces Schedule for Presentations at the 37th Annual Meeting and Exposition of the Controlled Release Society
4. Biodel Inc. Announces the Completion of Its Two Pivotal Trials and the Release of EASD Abstracts Containing Additional Interim Data From Its VIAject(TM) Program
5. Biodel Inc. Completes Enrollment of Two Pivotal Phase III Clinical Trials of VIAject(TM) and Plans Manufacturing Facility for VIAject(TM)
6. Biodel Inc. Expands Ongoing Phase III VIAject(TM) Clinical Trials Into Europe
7. Elsevier Launches International Journal of Surgery Case Reports
8. J.D. Power and Associates Reports: As Consumers Shoulder More Healthcare Expenses, Cost Increasingly Drives Overall Customer Satisfaction With Pharmacies
9. 12-Month Study Reports Efficacy Rates for AMS Elevate Apical and Posterior Prolapse Repair System
10. ChemoCentryx Reports Positive Results and Completion of Phase I Clinical Studies of Novel CCR2 Antagonist, CCX140, at the European Association for the Study of Diabetes (EASD)
11. Cyberonics Reports Inducement Equity Awards Under NASDAQ Listing Rule 5635(c)(4)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/6/2015)... CITY, Calif. , March 6, 2015  Abaxis, ... company manufacturing point-of-care instruments and consumables for the medical, ... services to the veterinary and research markets in ... the Center for Veterinary Biologicals of the U.S. Department ... Test Kit for the detection of   A. phagocytophelium ...
(Date:3/6/2015)... SAN FRANCISCO, Calif. , March 6, 2015 /PRNewswire/ ... today announced new data demonstrating that diagnostic tests that ... thyroid nodules can dramatically reduce the specificity of test ... which benign nodules are erroneously diagnosed as cancerous. In ... actually miss half of the malignancies leading to "false ...
(Date:3/6/2015)... 2015 UNICANCER pourra ... pouvant bénéficier de l,innovation thérapeutique.   ... de contenu pour l,Entreprise, annonce que sa solution ... Centres de lutte contre le cancer (CLCC), comme ... ConSoRe (Continuum Soin-Recherche) conduit par la société de ...
Breaking Medicine Technology:Abaxis, Inc. Announces USDA Clearance of VetScan Anaplasma Rapid Test 2Abaxis, Inc. Announces USDA Clearance of VetScan Anaplasma Rapid Test 3Veracyte Announces New Data that Inform Optimal Use of Molecular Testing in Preoperative Thyroid Nodule Assessment 2Veracyte Announces New Data that Inform Optimal Use of Molecular Testing in Preoperative Thyroid Nodule Assessment 3Veracyte Announces New Data that Inform Optimal Use of Molecular Testing in Preoperative Thyroid Nodule Assessment 4Veracyte Announces New Data that Inform Optimal Use of Molecular Testing in Preoperative Thyroid Nodule Assessment 5Veracyte Announces New Data that Inform Optimal Use of Molecular Testing in Preoperative Thyroid Nodule Assessment 6TEMIS et SWORD accompagnent UNICANCER pour accélérer la recherche par l'analyse sémantique des dossiers patients 2TEMIS et SWORD accompagnent UNICANCER pour accélérer la recherche par l'analyse sémantique des dossiers patients 3TEMIS et SWORD accompagnent UNICANCER pour accélérer la recherche par l'analyse sémantique des dossiers patients 4
... , COCKEYSVILLE, Maryland, November 2 ... Iron Phosphate Technology,to New Levels. , ... high-tech,batteries for industry, has expanded its range of lithium technologies ... phosphate,cell on the market. These large cells are designed for ...
... Shire plc (LSE: SHP, Nasdaq: SHPGY ... a major medical meeting from a Phase IIIb study of ... (methylphenidate transdermal system) in adolescents aged 13 to 17 years ... In addition, data regarding the pharmacokinetic profile of Daytrana in ...
Cached Medicine Technology:Saft Develops Super-Phosphate(TM) Technology for Rigorous Defense Applications 2Shire Reports Tolerability and Clinical Effects Results of Daytrana(R) (methylphenidate transdermal system) from Study in Adolescents with ADHD 2Shire Reports Tolerability and Clinical Effects Results of Daytrana(R) (methylphenidate transdermal system) from Study in Adolescents with ADHD 3Shire Reports Tolerability and Clinical Effects Results of Daytrana(R) (methylphenidate transdermal system) from Study in Adolescents with ADHD 4Shire Reports Tolerability and Clinical Effects Results of Daytrana(R) (methylphenidate transdermal system) from Study in Adolescents with ADHD 5Shire Reports Tolerability and Clinical Effects Results of Daytrana(R) (methylphenidate transdermal system) from Study in Adolescents with ADHD 6Shire Reports Tolerability and Clinical Effects Results of Daytrana(R) (methylphenidate transdermal system) from Study in Adolescents with ADHD 7
(Date:3/6/2015)... US Sports Football Camps expands its ... two non-contact specialty camps and one contact football camp. ... Training, located at Bowie State University and Riverdale Baptist ... skills, speed and strength of football athletes. The contact ... Marvin Graves, former quarterback in the Canadian Football League, ...
(Date:3/6/2015)... (PRWEB) March 06, 2015 At ... company, announced today the launch of its powerful, ... on healthy and sustainable products at any retailer ... is exhibiting at Expo West Booth 6054. ... by gluten-free, Kosher, non-GMO, organic, Paleo, and vegan, ...
(Date:3/6/2015)... March 06, 2015 Johnson & Johnson ... verdict on March 5, 2015 in Superior Court in ... court documents, a jury of 12 awarded Mrs. Perry ... being implanted with an Ethicon TVT Abbrevo plastic sling ... and three women also awarded $5 million in punitive ...
(Date:3/6/2015)... 06, 2015 First Choice Emergency Room ... new facility is located at 13351 W. Bowles Avenue, Littleton, ... team is ready 24-7 to provide the highest quality emergency ... Medical Director of First Choice Emergency Room Littleton. ... the South Metro Denver Chamber of Commerce and a medical ...
(Date:3/6/2015)... GA (PRWEB) March 06, 2015 ... announced the release of a Clostridium Difficile (C ... providers. The C Diff use case is the ... that span hospital acquired infections, chronic conditions, and ... platform, the C Diff solution flags at risk ...
Breaking Medicine News(10 mins):Health News:US Sports Camps to Host Three New Football Camps in Maryland 2Health News:Makeena Launches App that Makes Healthy and Sustainable Products More Affordable for Shoppers 2Health News:Makeena Launches App that Makes Healthy and Sustainable Products More Affordable for Shoppers 3Health News:Johnson & Johnson Hit with $5.7 Million Verdict in Pelvic Mesh Trial Announces Matthews & Associates Law Firm 2Health News:Johnson & Johnson Hit with $5.7 Million Verdict in Pelvic Mesh Trial Announces Matthews & Associates Law Firm 3Health News:First Choice Emergency Room Opens New Facility in Littleton, Colorado 2Health News:Jvion Predicts Patients at Risk of C Difficile Infection to Reduce Risk and Save Lives 2
... Breast Cancer Survivors , Breast cancer survivors, ... death from non-cancer causes than from breast cancer. ... are surviving longer, and many are dying of ... and colleagues with the National Cancer Institute of ...
... to treatment than those with HPV-negative tumors , , TUESDAY, ... patients whose tumors test positive for human papillomavirus (HPV) ... than those who test negative, a new study says. ... be responsible for most cervical cancers, has recently been ...
... Safety ... Net Partnerships, OAKLAND, Calif., ... 778 community benefit grants,totaling more than $29 million. The charitable contributions ... it,serves. Funds were pledged or paid in each of Kaiser Permanente,s ...
... Northwestern Memorial,HealthCare, corporate parent of Northwestern Memorial ... new members to the Northwestern,Memorial Foundation,s Boards of ... currently serves as president of the Friends of ... Northwestern Memorial Hospital,s,Campaign Steering Committee. Gordon is chairman ...
... Other Strength Patches (12.5, 50, 75 and 100 ... PriCara(TM), Division of,Ortho-McNeil-Janssen Pharmaceuticals, Inc. said today ... transdermal system) CII,patches sold by PriCara in the ... by Sandoz Inc. in the United States are ...
... Group Improve Claims Processing, ... Appointment Scheduling and Patient Statements, BIRMINGHAM, Ala., ... agreement with Huntsville Pediatric Associates,to provide MDr PracticeManager(TM), ... appointment scheduling, medical,billing, electronic claims submission, payment and ...
Cached Medicine News:Health News:Other highlights in the Feb. 12 JNCI 2Health News:Other highlights in the Feb. 12 JNCI 3Health News:Other highlights in the Feb. 12 JNCI 4Health News:Kaiser Permanente Approves $29 Million in Community Benefit Grants 2Health News:Kaiser Permanente Approves $29 Million in Community Benefit Grants 3Health News:Northwestern Memorial HealthCare and Northwestern Memorial Foundation Elect New Members to Board of Directors 2Health News:PriCara(TM) Recalls 25 mcg/hr DURAGESIC(R) (fentanyl transdermal system) CII Pain Patches 2Health News:Huntsville Pediatric Associates Selects DST Health Solutions' Practice Management Solution for Billing, Accounts Receivable 2
Kerrison (Micro) Laminectomie Rongeur, with ejector. 18 cm - 7 1/8, with thick footplate, small handle, 90 up-cutting, jaws 2 mm wide....
... ValveTM, Hakim, H-V Lumbar Valve ... for meeting the complex demands ... response causes the valve to ... present, eliminating the need for ...
Codman Hakim Programmable valve cylindrical offers the ability to optimize the opening pressure of a shunt system before and after implantation. A shunted patient's condition will often change over t...
Leadpoint Micro-Electrode Recording...
Medicine Products: